Comparative Pharmacology
Head-to-head clinical analysis: APLENZIN versus SERZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APLENZIN versus SERZONE.
APLENZIN vs SERZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupropion is an aminoketone antidepressant that inhibits the reuptake of norepinephrine and dopamine, with no significant effect on serotonin. The exact mechanism of antidepressant action is unknown but is thought to be mediated by noradrenergic and dopaminergic pathways.
Serzone (nefazodone) is a serotonin antagonist and reuptake inhibitor (SARI). It blocks postsynaptic 5-HT2 receptors and inhibits serotonin and norepinephrine reuptake, leading to increased serotonergic and noradrenergic neurotransmission.
APLENZIN (bupropion hydrobromide) extended-release tablets: Initial dose 174 mg orally once daily in the morning; after 4 days, increase to 348 mg once daily. Maximum dose 348 mg/day.
Initial 100 mg orally twice daily; titrate to 200-300 mg twice daily. Maximum 600 mg/day.
None Documented
None Documented
Mean terminal half-life of bupropion is 21 hours (SD ±9 hours). Steady state achieved within 8 days. Metabolites have longer half-lives: hydroxybupropion ~24 hours, threohydrobupropion ~37 hours, erythrohydrobupropion ~34 hours.
Terminal elimination half-life is 18-22 hours for nefazodone; steady-state achieved in 3-5 days.
Primarily renal (87% recovered in urine) with 10% fecal elimination. Unchanged bupropion accounts for <1% of renal excretion; metabolites (hydroxybupropion, threohydrobupropion, erythrohydrobupropion) predominate.
Primarily hepatic metabolism; <1% excreted unchanged renally; metabolites excreted in urine (approximately 85%) and feces (approximately 15%).
Category C
Category C
Antidepressant
Antidepressant